TB-500 dosage protocol

What the compound is

TB-500 is a therapeutic peptide derived from the active site of thymosin beta-4 (Tβ4) (PMID 41476424, PMID 38382158). Peptides are short chains of amino acids that regulate cellular functions and facilitate biochemical processes (PMID 41476424). It is identified as Ac-LKKTETQ (PMID 38382158). TB-500 is considered an unapproved peptide, operating largely outside of regulatory oversight, though its parent compound Tβ4 is also discussed (PMID 41966639).

How it is thought to work

TB-500, similar to other wound-healing peptides, promotes angiogenesis (the formation of new blood vessels), integrin-mediated extracellular matrix remodeling, and fibroblast activation (PMID 41490200). Its unacetylated form, LKKTETQ, has various biological functions including actin binding, dermal wound healing, and skin repair (PMID 38382158). TB-500 is thought to modulate molecular signaling networks central to cellular medicine, influencing tissue regeneration and inflammation resolution (PMID 41490200). Recent research suggests that the wound-healing activity attributed to TB-500 may be due to its metabolite, Ac-LKKTE, rather than the parent compound itself (PMID 38382158, cellular study).

What laboratory and animal studies report

In preclinical models, TB-500 and its parent compound TB-4 promoted angiogenesis and tissue repair (PMID 41476424). Animal models, most commonly rats, have shown that TB-500 has promising effects on tendon, muscle, bone, and ligament healing (PMID 42578445, animal studies). Studies in human serum and various in-vitro enzyme systems, as well as urine samples from rats treated with TB-500, have investigated its metabolism (PMID 38382158, cellular and animal studies). The primary metabolite in rats was Ac-LK (PMID 38382158, animal study). A long-term metabolite, Ac-LKK, was detected in rats up to 72 hours (PMID 38382158, animal study). In cellular experiments, Ac-LKKTE was found to have significant wound healing activity compared to a control, while the parent TB-500 and its metabolites showed no cytotoxicity (PMID 38382158, cellular study).

Human evidence so far

Rigorous human safety data for unapproved peptides like TB-500 are scarce (PMID 41966639). While preclinical studies are promising, there is a current lack of clinical trials for TB-500 (PMID 41490200). Human orthopaedic data specifically for TB-4 and TB-500 are lacking (PMID 41476424). Overall, human clinical studies on emerging peptides for musculoskeletal recovery and enhancement are limited, with most lacking robust controls or rigorous study designs (PMID 42578445).

Open questions and limitations

Despite promising findings in animal studies, the claimed benefits of emerging peptide supplements, including TB-500, for musculoskeletal recovery and performance remain unsubstantiated by current human trials (PMID 42578445). There is a significant lack of evidence to support the clinical use of TB-500 (PMID 41476424). TB-500 is a banned substance in sports (PMID 41476424). Significant knowledge gaps exist regarding optimal dosing regimens, combination therapy effects, and biomarkers for monitoring efficacy of investigational peptides (PMID 42021992).

Key terms explained

Peptide: A short chain of amino acids, which are the building blocks of proteins (PMID 41966639, PMID 41476424).

Angiogenesis: The formation of new blood vessels (PMID 41490200).

Extracellular matrix remodeling: The process of changing the complex network of proteins and other molecules that surround and support cells (PMID 41490200).

Fibroblast activation: The process by which fibroblasts, a common type of cell in connective tissue, become active in processes like wound healing (PMID 41490200).

Metabolite: A substance formed in or necessary for metabolism (PMID 38382158).